drugset / Trial / NCT00647868

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

NCT00647868

Phase 1 Completed 32 enrolled Acerus Pharmaceuticals Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

In this study the serum concentration of testosterone and its main metabolite DHT will be measured in hypogonadal men using intranasal testosterone (Nasobol). Different treatment regimens (once and twice daily) and administration times will be tested. The serum levels obtained will be compared with those of healthy men. It is expected that intranasal administration of Nasobol will restore testosterone and DHT levels to nearly normal.

Timeline

Start
2008-05
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 7.6 mg Intranasal

Indications